 CAMBRIDGE, Mass., April 07, 2022 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced the details of its webcast to discuss updated clinical data from the ongoing monotherapy Phase 1 arm of the Phase 12 clinical trial of RTX-240 in patients with advanced solid tumors and relapsedrefractory acute myeloid leukemia on April 8, 2022, at 1:15 p.m. ET. 